BTIG Maintains Buy on GEHC (GE HealthCare Technologies Inc.) Feb 04, 2026

BTIG maintained Buy on GEHC and raised its price target to $91 on Feb 04, 2026. This GEHC analyst rating follows GE HealthCare’s fourth-quarter 2025 results and signals continued conviction from BTIG. The change keeps a constructive stance while nudging upside expectations. Investors watching GE HealthCare Technologies Inc. should note the mix of a steady rating and a higher price target as a vote of confidence.

GEHC analyst rating: BTIG maintains Buy and raises price target

On Feb 04, 2026, BTIG kept a Buy rating on GEHC and lifted the price target to $91 from $87. The move followed GE HealthCare’s Q4 2025 results and reflects improved margin and revenue trajectory observed by BTIG. Read BTIG’s note via StreetInsider for details source.

Market reaction and stock movement after the rating action

The reported price change since the note is -6.02% or -$5.05. That decline shows short-term selling pressure despite the raised target. Investors should separate near-term volatility from analyst outlook shifts when evaluating GE HealthCare.

Other analyst activity and price target context

Piper Sandler recently raised its target to $94 while keeping an Overweight stance, adding to upside targets in the street. Multiple firms have nudged targets higher after Q4 results, tightening the range around $91 to $94. See the Piper Sandler update on Investing.com for background source.

What this GEHC analyst rating means for investors

A maintained Buy with a higher target signals confidence without adding immediate green lights. It means analysts see better earnings or margin visibility ahead. Investors should weigh the rating with valuation, risk tolerance, and the recent share move.

Historical analyst coverage and trend

Analyst coverage for GE HealthCare expanded after its spinout and through 2024–2025 earnings. Price targets have trended upward as revenue stabilized and service margins improved. The current cluster of targets near the low-to-mid $90s reflects converging expectations.

Meyka view and stock grade for GEHC

Meyka AI rates GEHC with a grade of B+. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Market cap stands at $37,707,459,379, which supports analyst attention and liquidity for institutional investors.

Final Thoughts

BTIG’s decision on Feb 04, 2026 to maintain Buy while raising the price target to $91 is a signal of continued analyst confidence in GE HealthCare. The GEHC analyst rating underscores better visibility into margins and revenue after Q4 2025, while other firms like Piper Sandler press targets slightly higher. For investors, the key takeaway is balance: analysts project upside but recent price movement shows short-term risk. Use the updated targets, the B+ Meyka Grade, and your risk profile to gauge position sizing. Remember, ratings and targets guide but do not guarantee outcomes. Meyka AI provides this analysis as an AI-powered market analysis platform, not financial advice.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Analyst ratings are opinions and not guarantees of future performance. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.